<DOC>
	<DOCNO>NCT00505843</DOCNO>
	<brief_summary>In clinical trial , safety MK0657 give levodopa assess patient Parkinson 's Disease . This study also measure effectiveness MK0657 , give combination levodopa , improve motor symptom ameliorate dyskinesia ( uncontrolled movement part body ) compare placebo .</brief_summary>
	<brief_title>A Study MK0657 Parkinson 's Disease Patients ( 0657-006 )</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Parkinson 's Disease patient age 40 80 inclusive Patient general good health base screen assessment Patient willing discontinue antiparkinson 's medication least 8 hour prior dose Patient levodopa responsive levodopainduced peakdose dyskinesias Patient take selective serotonin inhibitor ( SSRIs ) , sleep medication neuroleptic , stable dose least 30 day experience CNSrelated side effect Patient heavy smoker drinker Patient atypical Parkinson 's syndrome due drug , identify metabolic and/or neurologic disorder , encephalitis , degenerative syndrome Patient know intolerance hypersensitivity levodopa carbidopa Patient anticholinergic memantine within 30 day prior dose Patients history follow : seizure disorder , stroke head trauma , pronounce cognitive impairment , psychiatric disorder , cardiovascular disease , cancer , diabetes define HbA1c great 8 % Patient systolic BP le 80 mm Hg great 150 mm Hg</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>